- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2021-005775-39.
Displaying page 1 of 1.
EudraCT Number: 2021-005775-39 | Sponsor Protocol Number: INCAGN2385-203 | Start Date*: 2022-07-22 | |||||||||||
Sponsor Name:Incyte Biosciences International Sarl | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–P... | |||||||||||||
Medical condition: In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BE (Prematurely Ended) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) PT (Trial now transitioned) NL (Ongoing) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.